Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report.

Suyao LiQing LiuMengling LiuTian-Shu Liu

Published in: Cancer management and research (2022)

This is the first reported case of HER2 V842I mutation successfully treated with pyrotinib in BUC, suggesting pyrotinib therapy might serve as a therapeutic option for BUC patients harboring HER2 activating mutation.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
small cell lung cancer
squamous cell carcinoma
prognostic factors
signaling pathway
stem cells
peritoneal dialysis
mesenchymal stem cells
bone marrow
cell therapy